| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Jürgen Panholzer, Amadeus Hauser, Nadia Thamm, Gudrun Gröppel, Kurosch Yazdi-Zorn, Tim J von Oertze. Impact of depressive symptoms on adverse effects in people with epilepsy on antiseizure medication therapy. Epilepsia open. 2024-04-16. PMID:38625683. |
we studied the impact of depressive symptoms on adverse effects (aes) in people with epilepsy (pwe) on antiseizure medication (asm) therapy. |
2024-04-16 |
2024-04-18 |
Not clear |
| Biagio Maria Sancetta, Lorenzo Ricci, Jacopo Lanzone, Marilisa Boscarino, Flavia Narducci, Giulia Lippa, Marianna Nesta, Vincenzo Di Lazzaro, Mario Tombini, Giovanni Assenz. Overnight switch from carbamazepine to eslicarbazepine in a real-life clinical scenario: a retrospective study. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2024-02-05. PMID:38315252. |
we describe our experience of the overnight cbz to esl switch in people with epilepsy (pwe) to improve seizure control, aes, and asms adherence. |
2024-02-05 |
2024-02-09 |
Not clear |
| Yue Cao, Hua Li, Mingyue Chen, Pei Wang, Fanfan Shi, Xi Zhu, Anjiao Peng, Sheyu Li, Lei Che. Evaluation and systematic review of guidance documents for status epilepticus. Epilepsy & behavior : E&B. vol 150. 2023-12-21. PMID:38128315. |
notably, the 2016 guideline published by the american epilepsy society in epilepsy (aes) received the highest overall scores. |
2023-12-21 |
2023-12-24 |
Not clear |
| Stéphane Auvin, Aristea S Galanopoulou, Solomon L Moshé, Heidrun Potschka, Luisa Rocha, Matthew C Walke. Revisiting the concept of drug-resistant epilepsy: A TASK1 report of the ILAE/AES Joint Translational Task Force. Epilepsia. 2023-09-07. PMID:37676719. |
as the incidence of dre remains high, the task1 workgroup on dre of the ilae/american epilepsy society (aes) joint translational task force discussed the heterogeneity and complexity of its presentation and mechanisms, the confounders in drawing mechanistic insights when testing treatment responses, and barriers in modeling dre across the lifespan and translating across species. |
2023-09-07 |
2023-10-07 |
Not clear |
| Natalia Garza Philpott, Siddhartha A Dante, David Philpott, Jamie Perin, Pooja Bhatia, Eric Henderson, Philomena Costabile, Maera Stratton, Ania Dabrowski, Eric H Kossoff, Bruce L Klein, Corina Noj. Treatment Guideline Nonadherence Pretransport Associated With Need for Higher Level of Care in Children Transferred to a Pediatric Tertiary Care Center for Status Epilepticus. Pediatric emergency care. 2023-05-10. PMID:37163683. |
we sought to investigate the association between adherence to the american epilepsy society (aes) 2016 guidelines for management of convulsive status epilepticus (se) and clinical outcomes among children requiring interhospital transport for se. |
2023-05-10 |
2023-08-14 |
Not clear |
| Melissa Barker-Haliski, Julika Pitsch, Aristea S Galanopoulou, Rüdiger Köhlin. A companion to the preclinical common data elements for phenotyping seizures and epilepsy in rodent models. A Report of the TASK3-WG1C: Phenotyping Working Group of the ILAE/AES Joint Translational Task Force. Epilepsia open. 2022-12-03. PMID:36461665. |
to address this goal as part of the task3-wg1c working group of the international league against epilepsy (ilae) / american epilepsy society (aes) joint translational task force, we developed a case report form (crf) to describe the common data elements (cdes) necessary for the phenotyping of seizure-like behaviors in rodents. |
2022-12-03 |
2023-08-14 |
human |
| Jon A Cokley, Barry E Gidal, Joy A Keller, David G Vossle. Paxlovid Epilepsy currents. vol 22. issue 3. 2022-12-01. PMID:36451851. |
paxlovid this american epilepsy society (aes) official statement provides information and preliminary guidance to society members related to the u.s. food & drug administration (fda) december 22, 2021 emergency use authorization for paxlovid™ for the oral treatment of mild to moderate covid-19 in adults and children (≥12 years and weighing ≥40 kg). |
2022-12-01 |
2023-08-14 |
Not clear |
| Anna-Maria Katsarou, Hana Kubova, Stéphane Auvin, Massimo Mantegazza, Melissa Barker-Haliski, Aristea S Galanopoulou, Christopher A Reid, Bridgette D Sempl. A companion to the preclinical common data elements for rodent models of pediatric acquired epilepsy: A report of the TASK3-WG1B, Pediatric and Genetic Models Working Group of the ILAE/AES Joint Translational Task Force. Epilepsia open. 2022-08-11. PMID:35950641. |
to address this, as part of the task3-wg1b working group of the international league against epilepsy (ilae) / american epilepsy society (aes) joint translational task force, we have developed a series of case report forms (crfs) to describe common data elements (cdes) for pediatric acquired epilepsy models in rodents. |
2022-08-11 |
2023-08-14 |
Not clear |
| Massimo Mantegazza, Stėphane Auvin, Melissa Barker-Haliski, Anna-Maria Katsarou, Hana Kubova, Aristea S Galanopoulou, Bridgette Semple, Christopher A Rei. A companion to the preclinical common data elements for rodent genetic epilepsy models. A Report of the TASK3-WG1B: Pediatric and Genetic models Working Group of the ILAE/AES Joint Translational Task Force. Epilepsia open. 2022-08-11. PMID:35951766. |
here we present two case report forms (crfs) describing common data elements (cde) for genetic rodent models, developed by the task3-wg1b working group of the international league against epilepsy (ilae) / american epilepsy society (aes) joint translational task force. |
2022-08-11 |
2023-08-14 |
Not clear |
| Joyce Y Wu, Hannah R Cock, Orrin Devinsky, Charuta Joshi, Ian Miller, Colin M Roberts, Rocio Sanchez-Carpintero, Daniel Checketts, Farhad Sahebka. Time to Onset of Cannabidiol (CBD) Treatment Effect and Resolution of Adverse Events in Tuberous Sclerosis Complex: Post Hoc Analysis of Randomized Controlled Phase 3 Trial GWPCARE6. Epilepsia. 2022-02-17. PMID:35175622. |
to estimate the timing of cannabidiol (cbd) treatment effect (seizure reduction and adverse events [aes]) onset, we conducted a post hoc analysis of gwpcare6 (nct02544763), a randomized, placebo-controlled, phase 3 trial in patients with drug-resistant epilepsy associated with tuberous sclerosis complex (tsc). |
2022-02-17 |
2023-08-13 |
Not clear |
| L Abraira, J Salas-Puig, M Quintana, I M Seijo-Raposo, E Santamarina, E Fonseca, M Toled. Overnight switch from levetiracetam to brivaracetam. Safety and tolerability. Epilepsy & behavior reports. vol 16. 2021-12-13. PMID:34901817. |
this was a retrospective descriptive study including patients with epilepsy treated with levetiracetam, who switched due to inefficacy or previous adverse events (aes). |
2021-12-13 |
2023-08-13 |
Not clear |
| Jimmy Li, Dènahin Hinnoutondji Toffa, Elie Bou Assi, Sepehr Mehrpouyan, Julie Forand, Manon Robert, Mark Keezer, Adrien Flahault, Dang Khoa Nguye. Intervention Time and Adverse Events in a Canadian Epilepsy Monitoring Unit. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques. vol 48. issue 5. 2021-10-18. PMID:33308345. |
intervention time (it) in response to seizures and adverse events (aes) have emerged as key elements in epilepsy monitoring unit (emu) management. |
2021-10-18 |
2023-08-13 |
Not clear |
| Yew Li Dang, Emma Foster, Michael Lloyd, Genevieve Rayner, Maria Rychkova, Rashida Ali, Patrick W Carney, Dennis Velakoulis, Toby T Winton-Brown, Tomas Kalincik, Piero Perucca, Terence J O'Brien, Patrick Kwan, Charles B Malpa. Adverse events related to antiepileptic drugs. Epilepsy & behavior : E&B. vol 115. 2021-04-19. PMID:33360400. |
this study investigated the clinicodemographic factors associated with aes related to aeds as reported by the liverpool adverse events profile (laep), and explored the ability of laep to discriminate between epilepsy and psychogenic nonepileptic seizures (pnes). |
2021-04-19 |
2023-08-13 |
Not clear |
| Yew Li Dang, Emma Foster, Michael Lloyd, Genevieve Rayner, Maria Rychkova, Rashida Ali, Patrick W Carney, Dennis Velakoulis, Toby T Winton-Brown, Tomas Kalincik, Piero Perucca, Terence J O'Brien, Patrick Kwan, Charles B Malpa. Adverse events related to antiepileptic drugs. Epilepsy & behavior : E&B. vol 115. 2021-04-19. PMID:33360400. |
we hypothesized that female sex, mood disorders, aed-polytherapy, duration, and severity of epilepsy are associated with increased endorsement of aes related to aeds, and that endorsement of aes related to aeds would significantly differ between epilepsy and pnes patients. |
2021-04-19 |
2023-08-13 |
Not clear |
| Angela M Parsons, Akta A Patel, Amy Z Crepea. Treatment of Status Epilepticus: What Are the Guidelines and Are We Following Them? The neurologist. vol 25. issue 4. 2021-04-06. PMID:32618836. |
the american epilepsy society (aes) has established guidelines regarding proper dosing of antiepileptic drugs (aeds). |
2021-04-06 |
2023-08-13 |
Not clear |
| Juan G Ochoa, Michelle Dougherty, Alex Papanastassiou, Barry Gidal, Ismail Mohamed, David G Vossle. Treatment of Super-Refractory Status Epilepticus: A Review. Epilepsy currents. 2021-03-26. PMID:33719651. |
this review is a sequel to the 2020 american epilepsy society (aes) comprehensive review of the treatment of convulsive refractory status epilepticus (rse). |
2021-03-26 |
2023-08-13 |
Not clear |
| Timothy E Welty, Kevin E Chapman, R Edward Faught, Robert J Kotlosk. American Epilepsy Society (AES): Written Comments to Norman E. "Ned" Sharpless, MD, Acting Commissioner of Food and Drugs, U.S. Food and Drug Administration (FDA), Department of Health and Human Services (HHS): on Docket ID# FDA-2019-N-1482, Epilepsy currents. vol 19. issue 6. 2021-01-10. PMID:31640419. |
american epilepsy society (aes): written comments to norman e. "ned" sharpless, md, acting commissioner of food and drugs, u.s. food and drug administration (fda), department of health and human services (hhs): on docket id# fda-2019-n-1482, |
2021-01-10 |
2023-08-13 |
human |
| Jeremy M Welton, Christine Walker, Kate Riney, Alvin Ng, Lisa Todd, Wendyl J D'Souz. Quality of life and its association with comorbidities and adverse events from antiepileptic medications: Online survey of patients with epilepsy in Australia. Epilepsy & behavior : E&B. vol 104. issue Pt A. 2020-11-23. PMID:31954268. |
this study aimed to explore the quality of life (qol) of adult patients with epilepsy (pwe) in australia and its relationship with comorbidities and adverse events (aes) from antiepileptic drugs (aeds). |
2020-11-23 |
2023-08-13 |
Not clear |
| Sudhir C Sarangi, Nivendeep Kaur, Manjari Tripath. Need for pharmacoeconomic consideration of antiepileptic drugs monotherapy treatment in persons with epilepsy. Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society. vol 28. issue 10. 2020-11-03. PMID:33132717. |
this study evaluated variation in the cost of treatment with newer and conventional aeds through its correlation with treatment efficacy and aes in persons with epilepsy (pwe). |
2020-11-03 |
2023-08-13 |
Not clear |
| Alexandra Rohracher, Gudrun Kalss, Markus Leitinger, Claudia Granbichler, Ildiko Deak, Judith Dobesberger, Giorgi Kuchukhidze, Aljoscha Thomschewski, Julia Höfler, Eugen Trink. Two-year real-world experience with perampanel in patients with refractory focal epilepsy: Austrian data. Therapeutic advances in neurological disorders. vol 9. issue 6. 2020-10-01. PMID:27800020. |
the aim of this study was to analyse registry data of seizure outcome and adverse events (aes) for perampanel as add-on therapy in patients with focal epilepsy since its approval in 2012 for adjunctive treatment of focal epilepsy in patients ⩾12 years. |
2020-10-01 |
2023-08-13 |
Not clear |